Gerresheimer AG : Q4 review – strong end to 2022
>Strong organic growth converts to beat on sales - The company reported Q4 revenues of € 529m (+21.3% y-o-y), which were 4%/3% vs ODDO BHF/consensus. Organic growth was 15.9% and around 2 percentage points ahead of expectations. Primary packaging glass grew organically by 18.1% in the quarter, while Plastics & devices was up by 13.8%. The Advanced technologies division made revenues of €4m, as expected.Bottom line shows positive trend, also ahead of expec...Gerresheimer is a holding company. Through its subsidiaries, Co. manufactures glass and plastic products for the pharma and healthcare industry. Co.'s operates in three divisions: Plastics & Devices, which its product portfolio includes products for the administration of medicines, such as insulin pens, inhalers, and prefillable syringes; Primary Packaging Glass, which produces glass primary packaging for medicines and cosmetics, such as pharma jars, ampoules, injection vials, cartridges, perfume flacons, and cream jars; and Life Science Research, which produces laboratory glassware for research, development, and analytics, such as beakers, Erlenmeyer flasks, and measuring cylinders.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.